Mingwan0
Except for the following comments about interaction with other drugs, progression of the disease, as well as metabolism questions or emvironmental introductions into the body, this article has been written on this board many times.
These are issues I'm sure DNAP has encountered and are carefully coping with before they make public their studies.
Too, I'm glad to see mentioned again the importance of providing legislation to answer privacy issues.
"The authors also warn that it is difficult to conduct clinical trials that prove that individualized drug therapy based on genetics actually improves outcomes. Such trials could be complicated by several factors: multiple genes might influence patient response to the drug; there might be interaction with other drugs given simultaneously; and the seriousness or rate of progression of the disease as well as diet and activities such as smoking might affect treatment outcome.
"Despite the enthusiasm researchers have for advancing biomedical technology and exploring the human genome, there is little willingness to incorporate pharmacogenomics into clinical trials," Evans said.
What is needed, according to the authors, are large-scale clinical trials that incorporate comprehensive pharmacogenomic studies. In order to bring the significant potential benefits of pharmacogenomics to the public, medical practice has to evolve from the trial-and-error approach. For that to happen, society must institute protections against misuse of genetic information."
News 
Market Data 
Discover 
